JAMA Intern Med:单药治疗社区获得性肺炎无双药治疗有效

2014-10-09 刘玉华(编译) 医学论坛网

根据《美国医学会杂志•内科学杂志》(JAMA•Internal Medicine )10月6日在线发布的一项开放性非劣效性研究,单用ß-内酰胺类抗生素治疗社区获得性肺炎并没有ß-内酰胺类抗生素联用大环内酯类有效。 瑞士研究人员将近600名因社区获得性肺炎收入院的成人患者随机分配至单用ß-内酰胺类抗生素(以阿莫西林-克拉维酸常用)组或ß-内酰胺类抗生素和大环内酯类(克拉

根据《美国医学会杂志•内科学杂志》(JAMA•Internal Medicine )10月6日在线发布的一项开放性非劣效性研究,单用ß-内酰胺类抗生素治疗社区获得性肺炎并没有ß-内酰胺类抗生素联用大环内酯类有效。

瑞士研究人员将近600名因社区获得性肺炎收入院的成人患者随机分配至单用ß-内酰胺类抗生素(以阿莫西林-克拉维酸常用)组或ß-内酰胺类抗生素和大环内酯类(克拉霉素)双药联合治疗组。

研究结果显示,治疗7天时,单药治疗组中41%的患者为非临床稳定状态(主要研究终点),相较之下,双药联合治疗组的这一比例为34%。尽管两组间的差异性并不显著,但是并不能认为单药治疗非劣于双药联合治疗。而且在携带非典型性病原体患者中,双药联合治疗更具优势。

评论人员称,在未开展其他试验前,双药联合治疗仍应作为社区获得性肺炎住院患者的推荐治疗方案。

原始出处:

Garin N1, Genné D2, Carballo S3, Chuard C4, Eich G5, Hugli O6, Lamy O7, Nendaz M3, Petignat PA8, Perneger T9, Rutschmann O10, Seravalli L2, Harbarth S11, Perrier A3.β-Lactam Monotherapy vs β-Lactam-Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia: A Randomized Noninferiority Trial.JAMA Intern Med. 2014 Oct 6. doi: 10.1001/jamainternmed.2014.4887. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042549, encodeId=a8ee2042549b5, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri Jan 30 15:52:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687677, encodeId=647b168e67788, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Aug 17 21:52:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395606, encodeId=45e613956060c, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606298, encodeId=52ff1606298bf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2042549, encodeId=a8ee2042549b5, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri Jan 30 15:52:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687677, encodeId=647b168e67788, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Aug 17 21:52:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395606, encodeId=45e613956060c, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606298, encodeId=52ff1606298bf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2042549, encodeId=a8ee2042549b5, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri Jan 30 15:52:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687677, encodeId=647b168e67788, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Aug 17 21:52:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395606, encodeId=45e613956060c, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606298, encodeId=52ff1606298bf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2042549, encodeId=a8ee2042549b5, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri Jan 30 15:52:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687677, encodeId=647b168e67788, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Aug 17 21:52:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395606, encodeId=45e613956060c, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606298, encodeId=52ff1606298bf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 11 04:52:00 CST 2014, time=2014-10-11, status=1, ipAttribution=)]

相关资讯

ECCMID 2014 :头孢洛林对亚洲社区获得性肺炎患者疗效较佳

第24届欧洲临床微生物学和感染性疾病学术会(ECCMID)于2014年5月10日-13日在西班牙巴塞罗那召开,会议报道了一项治疗亚洲社区获得性肺炎III期临床试验结果:头孢洛林酯在治疗社区获得性肺炎患者时效果优于头孢曲松。Medscape医学新闻对此研究结果进行了报道,现将主要内容编译如下。 头孢曲松和头孢洛林都属于头孢菌素类注射用抗生素,尽管该试验结果表明后者疗效在治疗亚洲社区获得性肺炎方

BMJ:社区获得性肺炎(CAP)患者入院时血糖水平高,预示死亡风险增加

Fig 1Cumulative incidence of death (%) within 90 days in participants with community acquired pneumonia stratified by serum glucose levels on admission overall (n=6016) (top) and without diabetes (n=5

BMJ:COPD患者用克拉霉素增加心血管事件

  英国学者的一项研究显示,在慢性阻塞性肺疾病(COPD)急性加重期或社区获得性肺炎患者中应用克拉霉素与心血管事件风险增高有关。这些结果需要在其他数据库中进行验证。相关论文发表于BMJ杂志。   该研究包括2项前瞻性收集数据库数据的分析,一项为COPD数据库包括2009年~2011年之间,全英国范围内12家医院住院患者;另一项为爱丁堡肺炎队列研究包括2005年~2009年之间进入NHS 

美国婴幼儿及儿童社区获得性肺炎(CAP)指南公布

  为有效预防、诊治婴幼儿及儿童社区获得性肺炎(CAP),儿科感染性疾病学会(PIDS)和美国感染性疾病学会(IDSA)共同出台了其首个婴幼儿及儿童CAP诊治指南。整部指南共涉及诊断、治疗、预防等20个方面、92条推荐意见。该指南8月30日在线发布于《临床感染性疾病杂志》(Clin Infect Dis)。   现将其中有关何种患儿须住院治疗、门诊CAP可疑患儿应接受何种检查

Arch Pediatr Adolesc Med:诊断儿童肺炎 即时超声比听诊更准确

       《儿科学与青少年疾病文献集》在线发表了芒特西奈(位于纽约的医学中心)研究人员的一篇文章,名为“即时超声检查对儿童和年轻人肺炎诊断的评估前景”。文中指出即时超声检查比经典的听诊器听诊对诊断儿童和年轻人肺炎更为准确,甚至可以发现胸部X线片漏诊的轻微肺炎。          肺炎是全球儿童死

Pediatrics:质量改进可促进儿童肺炎抗菌药物合理使用

  美国学者的一项研究表明,即使没有支持社区获得性肺炎(CAP)的慎重抗菌药处方的正式抗菌药物管理工作计划,质量改进(QI)方法也能迅速改善对国家指南的依从性。 相关论文发表于《儿科》杂志。  相关论文发表于   该研究纳入美国辛辛那提儿童医院医学中心的CAP患儿,使用QI方法来快速实现儿科传染病学会/美国传染病学会指南建议的合理一线抗菌药物治疗。QI干预集中在4个关键点,并